Literature DB >> 6131277

JMS, successor to cisplatin in advanced ovarian carcinoma?

E Wiltshaw, B D Evans, A C Jones, J W Baker, A H Calvert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6131277     DOI： 10.1016/s0140-6736(83)92834-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Carboplatin is ototoxic.

Authors:  I C Kennedy; B M Fitzharris; B M Colls; C H Atkinson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  Chemotherapy in advanced ovarian cancer.

Authors:  C J Rodenburg; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).

Authors:  A C Jones; P A Wilson; G G Steel
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.

Authors:  C L Bregman; P D Williams
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.

Authors:  E K Mbidde; S J Harland; A H Calvert; I E Smith
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Potentiation of platinum analogue cytotoxicity by hyperthermia.

Authors:  M J Xu; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.

Authors:  P A Steerenberg; C P Vendrik; W H de Jong; G de Groot; A M Fichtinger-Schepman; A P Scheefhals; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.

Authors:  P Dodion; C Sanders; P Georges; Y Kenis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.